Analysis of organ function and comrbidity parameters, as well as established multiple myelom prognosis factors as structured, sysematic aquisition of age-associated concomitant factors and their prognostic relevance for evidence based assertions concerning therapy tolerance and survival in myelom patients.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003868

Enrollment

100

Registered

2015-01-28

Start date

2011-10-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90

Interventions

Group 1: The effort to capture co-morbidities in myeloma patients , partly the result of the realization that myeloma patients is a typically older patients clientele with an average of 69 years ( at

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed or recurrent requiring therapy for multiple myeloma

Exclusion criteria

Exclusion criteria: No need of therapy of multiple myeloma

Design outcomes

Primary

Measure	Time frame
Detection of comorbidities (MM -specific factors , organ function, function assessment) in patients with multiple myeloma and their influence on the Ereignisfreie- and overall survival.	—

Secondary

Measure	Time frame
1. Detection of already established comorbidity scores ( HCT -CI , Kaplan- Feinstein ) and compared with a newly developed myeloma- specific score. 2.Evaluation a weighted vs. unweighted MM specific comorbidity score. 3.Evaluation of comorbidity scores to make a prediction regarding . Therapy tolerability / toxicity of chemotherapy can . 4. Influence of therapy concepts retrospectively in the period 1997-2003 compared with new Therapieagentien in time from 2003 to 2009 on the Ereignisfreie- and overall survival in patients with multiple myeloma.	—

Measure

Time frame

1. Detection of already established comorbidity scores ( HCT -CI , Kaplan- Feinstein ) and compared with a newly developed myeloma- specific score. 2.Evaluation a weighted vs. unweighted MM specific comorbidity score. 3.Evaluation of comorbidity scores to make a prediction regarding . Therapy tolerability / toxicity of chemotherapy can . 4. Influence of therapy concepts retrospectively in the period 1997-2003 compared with new Therapieagentien in time from 2003 to 2009 on the Ereignisfreie- and overall survival in patients with multiple myeloma.

—

Countries

Germany

Contacts

Public ContactMonika Engelhardt

Universitätsklinikum Freiburg

monika.engelhardt@uniklinik-freiburg.de0761 270 32460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026